Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved ...

Eli Lilly and Company’s LLY shares have risen 4.3% since it reported fourth-quarter results on Feb. 6. Lilly’s fourth-quarter ...

The small, 48-subject study – published ... in Boston is running a four-week pilot study comparing Eli Lilly's dual GIP/GLP-1 tirzepatide to placebo in around 20 AUD patients, focusing on ...

Novo Nordisk’s NVO amycretin, which targets GLP-1 and amylin in one molecule, generated 24% placebo ... Novo has struggled to stay competitive with Eli Lilly LLY in developing the next ...

In obesity, Lilly removed a dual amylin calcitonin receptor agonist (DACRA) from its phase 1 pipeline. Lilly got into DACRAs by partnering with KeyBioscience in 2017. At one time, the Big Pharma was ...

Here are the small steps they're taking this year to get there. There is only one GLP-1 pill on the market, and it's not as effective as Ozempic for weight loss.Grace Cary/Getty Images Eli Lilly ...

Eli Lilly (NYSE: LLY) announced its full results and reiterated its earlier 2025 forecast. The company has been a big beneficiary of GLP-1 drugs that have seen soaring demand as they have been ...